Explore ESSA Pharma Inc.'s financial standing as of Dec 31, 2024. With no revenue and legal challenges, a 'Hold' recommendation is advised for investors.
Discover EDAP TMS S.A.'s impressive Q4 2024 preliminary results, featuring record Focal One sales and a 30% growth in U.S. prostate cancer procedures. Learn about future expectations and risks.
Explore EDAP TMS S.A.'s latest financial insights, including board member appointment, Focal One platform expansion, and strategic focus on HIFU technology applications.
Explore ESSA Pharma Inc.'s financial performance, stock recommendation, and market challenges. Key insights on liquidity, clinical trial setbacks, and future outlook for investors.